Insider · CIK 0001881403
Christopher Benecchi
cooofficer
Files at SAGE (Sage Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Common Stock | -28,053 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Common Stock | -36,375 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,000 | - | - | 0 | Jul 31, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +3,255 | $0.00 | $0 | 47,170 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -793 | $6.91 | $5,480 | 46,377 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +2,712 | $0.00 | $0 | 49,089 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -661 | $6.91 | $4,568 | 48,428 | Apr 11, 2025 |
| Feb 13, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -822 | $7.18 | $5,902 | 43,915 | Feb 14, 2025 |
| Jan 16, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 44,737 | Jan 21, 2025 |
| Jan 16, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Options (Right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 21, 2025 |
| Nov 1, 2024 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 24,737 | Nov 14, 2024 |
| Nov 1, 2024 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Nov 14, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.